I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Jack Anders Biography and Net Worth

Insider of Revolution Medicines

Jack has always had a keen interest in numbers and analytics, but also wanted to be part of teams that focus on improving patients’ lives. Those interests led him into to focusing on the business aspects of biotech organizations.

Jack brings approximately 20 years of finance and accounting experience to Revolution Medicines. Before joining Revolution, Jack was Vice President of Finance at Depomed, Inc., where he spent the last 12 years in various roles with increasing responsibilities including financial planning and analysis, commercial finance, accounting operations and external reporting. At Depomed, Jack helped build and lead the finance and accounting organizations as the company transformed from a drug development company to a commercial pharmaceutical company which raised over $1 billion in financing, completed four asset acquisitions and grew to revenues of over $400 million. Prior to Depomed, Jack had various managerial roles in finance and accounting at Elan Pharmaceuticals, Yahoo! and Novellus Systems. He started his career in the life sciences practice at PricewaterhouseCoopers and is a former CPA.

Jack received his bachelor’s degree from UCLA in Economics with an emphasis in Accounting.

What is Jack Anders' net worth?: The estimated net worth of Jack Anders is at least $4.25 million as of December 16th, 2024. Mr. Anders owns 96,470 shares of Revolution Medicines stock worth more than $4,250,468 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Anders may own. Additionally, Mr. Anders receives a salary of $665,280.00 as Insider at Revolution Medicines. Learn More about Jack Anders' net worth.
How old is Jack Anders?: Mr. Anders is currently 47 years old. There are 5 older executives and no younger executives at Revolution Medicines. The oldest executive at Revolution Medicines is Dr. Stephen M. Kelsey FRC Path., FRCP, M.D., President of Research & Development, who is 63 years old. Learn More on Jack Anders' age.
What is Jack Anders' salary?: As the Insider of Revolution Medicines, Inc., Mr. Anders earns $665,280.00 per year. There are 3 executives that earn more than Mr. Anders. The highest earning executive at Revolution Medicines is Dr. Mark A. Goldsmith Ph.D., CEO, President & Chairman, who commands a salary of $1,120,000.00 per year. Learn More on Jack Anders' salary.
How do I contact Jack Anders?: The corporate mailing address for Mr. Anders and other Revolution Medicines executives is 700 Saginaw Drive, Redwood City CA, 94063. Revolution Medicines can also be reached via phone at 650-481-6801 and via email at [email protected]. Learn More on Jack Anders' contact information.
Has Jack Anders been buying or selling shares of Revolution Medicines?: Over the course of the past ninety days, Jack Anders has sold $622,629.00 of Revolution Medicines stock. Most recently, Jack Anders sold 2,635 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $45.40, for a transaction totalling $119,629.00. Following the completion of the sale, the chief financial officer now directly owns 96,470 shares of the company's stock, valued at $4,379,738. Learn More on Jack Anders' trading history.
Who are Revolution Medicines' active insiders?: Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?: In the last twelve months, Revolution Medicines insiders bought shares 1 times. They purchased a total of 1,304,347 shares worth more than $59,999,962.00. In the last twelve months, insiders at the sold shares 28 times. They sold a total of 271,841 shares worth more than $11,976,056.91. The most recent insider tranaction occured on December, 16th when COO Margaret A Horn sold 4,329 shares worth more than $196,536.60. Insiders at Revolution Medicines own 8.0% of the company. Learn More about insider trades at Revolution Medicines.
Information on this page was last updated on 12/16/2024.

Jack Anders Insider Trading History at Revolution Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/16/2024	Sell	2,635	$45.40	$119,629.00	96,470
10/11/2024	Sell	10,000	$50.30	$503,000.00	98,932
5/3/2024	Sell	10,000	$40.03	$400,300.00	101,959
3/18/2024	Sell	1,261	$31.58	$39,822.38	101,959
12/18/2023	Sell	1,775	$25.90	$45,972.50	76,416
9/18/2023	Sell	1,427	$31.31	$44,679.37	53,667
9/1/2023	Sell	20,000	$35.05	$701,000.00	55,094
6/20/2023	Sell	1,249	$24.89	$31,087.61	55,094
3/17/2023	Sell	665	$21.78	$14,483.70	55,233
12/19/2022	Sell	658	$22.94	$15,094.52	29,298
9/19/2022	Sell	449	$19.04	$8,548.96	29,956
12/17/2021	Sell	170	$24.41	$4,149.70
9/17/2021	Sell	166	$30.02	$4,983.32
10/13/2020	Sell	10,000	$44.00	$440,000.00	10,000
10/6/2020	Sell	10,000	$40.00	$400,000.00	10,000

Jack Anders Buying and Selling Activity at Revolution Medicines

Revolution Medicines Company Overview

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $44.06

$42.53

$44.22

50 Day Range

MA: $51.85

$42.97

$60.60

2 Week Range

Now: $44.06

$25.91

$62.40

Volume

2,673,471 shs

Average Volume

1,401,604 shs

Market Capitalization

$7.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.

Jack Anders Biography and Net Worth

What is Jack Anders' net worth?

How old is Jack Anders?

What is Jack Anders' salary?

How do I contact Jack Anders?

Has Jack Anders been buying or selling shares of Revolution Medicines?

Who are Revolution Medicines' active insiders?

Are insiders buying or selling shares of Revolution Medicines?